Endogenous inhibitors of angiogenesis

Cancer Research

Volumn 65, Issue 10, 2005, Pages 3967-3979

  Nyberg, Pia ^a   Xie, Liang ^a   Kalluri, Raghu ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ALPHA INTERFERON; ANASTELLIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTITHROMBIN III; ARRESTEN; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; BETA1 INTEGRIN; CALRETICULIN; CANSTATIN; CASPASE 8; CASPASE 9; CD31 ANTIGEN; CHRONDROMODULIN 1; COLLAGEN TYPE 15; COLLAGEN TYPE 18; COLLAGEN TYPE 4; COLLAGENASE 3; CYCLIN D1; ENDOREPELLIN; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENTACTIN; FAS LIGAND; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; FIBULIN; FOCAL ADHESION KINASE; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GELATINASE B; GROWTH FACTOR; HEMOPEXIN; HYPOXIA INDUCIBLE FACTOR 1; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 8; LAMININ; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTROPHIL COLLAGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROLACTIN; PROTEIN KINASE B; PROTEIN P53; PROTEOHEPARAN SULFATE; PROTHROMBIN; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TROPONIN I; TUMSTATIN; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASOSTATIN; VERY LATE ACTIVATION ANTIGEN 1;

ANGIOGENESIS; BASEMENT MEMBRANE; CANCER GROWTH; CANCER INHIBITION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 20144379162     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2427     Document Type: Review

References (209)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
4. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003;13:159-67.
5. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest 1999;103:157-8.
6. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-69.
7. Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 1996;8:618-24.
8. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403-34.
9. Madri JA. Extracellular matrix modulation of vascular cell behaviour. Transpl Immunol 1997;5:179-83.
10. Colorado PC, Torre A, Kamphaus G, et al. Antiangiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60:2520-6.
11. Grant DS, Kibbey MC, Kinsella JL, Cid MC, Kleinman HK. The role of basement membrane in angiogenesis and tumor growth. Pathol Res Pract 1994;190:854-63.
12. 1 integrins. Proc Natl Acad Sci U S A 1997;94:13612-7.
13. 1 Integrin is essential for teratoma growth and angiogenesis. J Cell Biol 1997;139:265-78.
14. 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 2000;97:2202-7.
15. 1 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol 1998;142:587-94.
16. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002;21:272-81.
17. Keller KM, Keller JM, Kuhn K. The C-terminus of type I collagen is a major binding site for heparin. Biochim Biophys Acta 1986;882:1-5.
18. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-15.
19. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003;278:37632-6.
20. Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000;275:8051-61.
21. Yurchenco PD, O'Rear JJ. Basal lamina assembly. Curr Opin Cell Biol 1994;6:674-81.
22. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 2003;278:4238-49.
23. 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol 1992;119: 945-59.
24. 1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 1997;250:39-46.
25. Talts JF, Andac Z, Gohring W, Brancaccio A, Timpl R. Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, α-dystroglycan and several extracellular matrix proteins. EMBO J 1999;18: 863-70.
26. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
27. Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG, Preissner KT. Isolation and characterization of the circulating form of human endostatin. FEBS Lett 1997;420:129-33.
28. Rehn M, Hintikka E, Pihlajaniemi T. Primary structure of the α1-chain of mouse type XVIII collagen, partial structure of the corresponding gene, and comparison of the α1(XVIII) chain with its homologue, the α1(XV) collagen chain. J Biol Chem 1994;269:13929-35.
29. Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci U S A 1994;91:4229-33.
30. Marneros AG, Olsen BR. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol 2001;20:337-45.
31. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
32. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 2002;62:1944-7.
33. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999;258:345-52.
34. 1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002;277: 16464-9.
35. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-9.
36. Yin G, Liu W, An P, et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002;5:547-54.
37. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J 2001;15:1044-53.
38. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
39. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001;98:1024-9.
40. 1 integrins. Proc Natl Acad Sci U S A 2003; 100:4766-71.
41. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 1998;94:625-34.
42. 1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62:5580-9.
43. Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003;536:19-24.
44. Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci U S A 2004;101:8005-10.
45. Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000;95:3403-11.
46. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-22.
47. Hohenester E, Sasaki T, Olsen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 1998;17:1656-64.
48. Sasaki T, Larsson H, Kreuger J, et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 1999;18:6240-8.
49. Kreuger J, Matsumoto T, Vanwildemeersch M, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J 2002;21:6303-11.
50. Wickstrom SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004.
51. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-3.
52. Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002;519:147-52.
53. Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, 9 and -13. J Biol Chem 2003.
54. Wickstrom SA, Veikkola T, Rehn M, Pihlajaniemi T, Alitalo K, Keski-Oja J. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res 2001;61:6511-6.
55. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
56. Ackley BD, Crew JR, Elamaa H, Pihlajaniemi T, Kuo CJ, Kramer JM. The NC1/endostatin domain of Caenorhabditis elegans type XVIII collagen affects cell migration and axon guidance. J Cell Biol 2001;152:1219-32.
57. Kuo CJ, LaMontagne KR Jr, Garcia-Cardena G, et al. Oligomerization- dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol 2001;152:1233-46.
58. Kranenburg O, Bouma B, Kroon-Batenburg LM, et al. Tissue-type plasminogen activator is a multiligand cross-β structure receptor. Curr Biol 2002;12:1833-9.
59. Olsen BR. From the editor's desk. Matrix Biol 2002;21:309-10.
60. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002;21:1535-44.
61. Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999;255:735-9.
62. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000;301:1179-90.
63. Ylikarppa R, Eklund L, Sormunen R, et al. Double knockout mice reveal a lack of major functional compensation between collagens XV and XVIII. Matrix Biol 2003;22:443-8.
64. Pasqualini R, Bourdoulous S, Koivunen E, Woods VL Jr, Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 1996;2:1197-203.
65. Yi M, Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A 2001;98:620-4.
66. Yi M, Sakai T, Fassler R, Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci U S A 2003;100:11435-8.
67. Kalluri R. Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Symp Quant Biol 2002;67:255-66.
68. Albig AR, Schiemann WP. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 2004;23:367-79.
69. Nguyen AD, Itoh S, Jeney V, et al. Fibulin-5 is a novel binding protein for extracellular superoxide dismutase. Circ Res 2004;95:1067-74.
70. Lee MJ, Roy NK, Mogford JE, Schiemann WP, Mustoe TA. Fibulin-5 promotes wound healing in vivo. J Am Coll Surg 2004;199:403-10.
71. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
72. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000;19:597-614.
73. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004;36:1070-8.
74. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 2002;161:831-9.
75. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
76. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001;98:12485-90.
77. Stellmach V, Volpert OV, Crawford SE, Lawler J, Hynes RO, Bouck N. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer 1996;32A:2394-400.
78. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994;59:191-5.
79. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 2001;159:1949-56.
80. Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD, Blake DA. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1 [in process citation]. Invest Ophthalmol Vis Sci 2000;41:2378-88.
81. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999;100:1423-31.
82. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
83. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A 1999;96:14888-93.
84. Hawighorst T, Velasco P, Streit M, et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 2001;20:2631-40.
85. Streit M, Stephen AE, Hawighorst T, et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 2002;62:2004-12.
86. Noh YH, Matsuda K, Hong YK, et al. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 2003;121:1536-43.
87. Monboisse JC, Garnotel R, Bellon G, et al. The α3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J Biol Chem 1994;269: 25475-82.
88. Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA. A cell binding domain from the α3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 1997;272:20395-401.
89. 3(IV) chain of type IV collagen on tumor cells. Cancer Res 1999;59:4584-90.
90. Maeshima Y, Colorado PC, Torre A, et al. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-8.
91. 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000;275:23745-50.
92. Pasco S, Ramont L, Maquart FX, Monboisse JC. Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol 2004;49:221-33.
93. Floquet N, Pasco S, Ramont L, et al. The antitumor properties of the α3(IV)-(185-203) peptide from the NCl domain of type IV collagen (tumstatin) are conformation-dependent. J Biol Chem 2004;279:2091-100.
94. Imagawa W, Pedchenko VK, Helber J, Zhang H. Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis. J Steroid Biochem Mol Biol 2002;80:213-30.
95. Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane derived tumstatin. J Biol Chem 2001;276:15240-8.
96. Maeshima Y, Yerramalla UL, Dhanabal M, et al. Extracellular matrix-derived peptide binds to α(v)β(3) integrin and inhibits angiogenesis. J Biol Chem 2001; 276:31959-68.
97. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-3.
98. Hutchings H, Ortega N, Plouet J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J 2003;17:1520-2.
99. 3 integrin. Cancer Cell 2003;3:589-601.
100. Caudroy S, Cucherousset J, Lorenzato M, et al. Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas. Hum Pathol 2004;35:1218-22.
101. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.
102. Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004;53:1831-40.
103. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998;8:171-7.
104. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-5.
105. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-52.
106. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 2001;44:757-65.
107. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 1994;79:315-28.
108. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998;37:4699-702.
109. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-10.
110. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274:29568-71.
111. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 1997;272:20641-5.
112. Ji WR, Castellino FJ, Chang Y, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998;12:1731-8.
113. Geiger JH, Cnudde SE. What the structure of angiostatin may tell us about its mechanism of action. J Thromb Haemost 2004;2:23-34.
114. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96:2811-6.
115. Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J Biol Chem 2002;277:33564-70.
116. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin α(v)β(3) in endothelial cells. J Biol Chem 2001;276:39562-8.
117. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152:1247-54.
118. Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 1998;95:5579-83.
119. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
120. Lee TH, Rhim T, Kim SS. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 1998;273:28805-12.
121. Kusafuka K, Hiraki Y, Shukunami C, Kayano T, Takemura T. Cartilage-specific matrix protein, chondromodulin-I (ChM-I), is a strong angio-inhibitor in endochondral ossification of human neonatal vertebral tissues in vivo: relationship with angiogenic factors in the cartilage. Acta Histochem 2002;104:167-75.
122. Shukunami C, Yamamoto S, Tanabe T, Hiraki Y. Generation of multiple transcripts from the chicken chondromodulin-I gene and their expression during embryonic development. FEBS Lett 1999;456:165-70.
123. Hayami T, Shukunami C, Mitsui K, et al. Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett 1999;458:436-40.
124. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-8.
125. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993;90:10705-9.
126. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene 1998;208:297-305.
127. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999;13:537-45.
128. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996;7:213-21.
129. Barleon B, Totzke F, Herzog C, et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 1997;272:10382-8.
130. Belgore FM, Blann AD, Lip GY. sFlt-1, a potential antagonist for exogenous VEGF. Circulation 2000;102: E108-9.
131. Yoshimura I, Mizuguchi Y, Miyajima A, Asano T, Tadakuma T, Hayakawa M. Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J Urol 2004;171:2467-70.
132. Ohtani K, Egashira K, Hiasa K, et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation 2004;110:2444-52.
133. Mitsuyasu RT. Interferon α in the treatment of AIDS-related Kaposi's sarcoma. Br J Haematol 1991; 79:69-73.
134. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon α act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998;58:5551-8.
135. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 1994;55:419-34.
136. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: critical role of STAT-1α. J Immunol 2001;167:5150-9.
137. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res 1998;58:808-14.
138. Ribatti D, Crivellato E, Candussio L, et al. Angiogenic activity of rat mast cells in the chick embryo chorioallantoic membrane is down-regulated by treatment with recombinant human α-2a interferon and partly mediated by fibroblast growth factor-2. Haematologica 2002;87:465-71.
139. Lopez-Ocejo O, Perea SE, Bequet-Romero M, Arana MJ, Lopez Saura P. Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-α. Biochem Biophys Res Commun 2000;277:410-6.
140. Nilsson A, Janson ET, Eriksson B, Larsson A. Levels of angiogenic peptides in sera from patients with carcinoid tumours during α-interferon treatment. Anticancer Res 2001;21:4087-90.
141. Sasamura H, Takahashi A, Miyao N, et al. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer 2002;86:768-73.
142. Wang L, Wu WZ, Sun HC, et al. Mechanism of interferon α on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003;7: 587-94.
143. Stricter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348-57.
144. Cozzolino F, Torcia M, Aldinucci D, et al. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci U S A 1990;87:6487-91.
145. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J 2004;18:161-3.
146. Volpert OV, Fong T, Koch AE, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188:1039-46.
147. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
148. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
149. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93:1612-21.
150. Yao L, Pike SE, Setsuda J, et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 2000;96:1900-5.
151. Johansson M, Henriksson R, Bergenheim AT, Koskinen LO. Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma. Br J Cancer 2000;83:826-32.
152. Morini M, Albini A, Lorusso G, et al. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. Gene Ther 2004;11:284-91,
153. Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 1999;13:2195-202.
154. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 1994;91:3964-8.
155. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 1997;51:951-62.
156. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002;531:141-51.
157. 2-M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res 2004;24:873-80.
158. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000;19:173-9.
159. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004;53:209-19.
160. Huang CY, Fujimura M, Noshita N, Chang YY, Chan PH. SOD1 down-regulates NF-κB and c-Myc expression in mice after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001;21:163-73.
161. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995;38:2041-9.
162. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
163. Duh EJ, Yang HS, Haller JA, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 2004;137:668-74.
164. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002;296:877-82.
165. Ogata N, Tombran-Tink J, Nishikawa M, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001;132:378-82.
166. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002;134:348-53.
167. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002;8:330-4.
168. Gettins PG, Simonovic M, Volz K. Pigment epithelium-derived factor (PEDF), a serpin with potent anti-angiogenic and neurite outgrowth-promoting properties. Biol Chem 2002;383:1677-82.
169. Coljee VW, Rotenberg MO, Tresini M, Francis MK, Cristofalo VJ, Sell C. Regulation of EPC-1/PEDF in normal human fibroblasts is posttranscriptional. J Cell Biochem 2000;79:442-52.
170. Abe R, Shimizu T, Yamagishi S, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004;164:1225-32.
171. Abramson LP, Stellmach V, Doll JA, Cornwell M, Arensman RM, Crawford SE. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J Pediatr Surg 2003;38:336-42; discussion 336-42.
172. Crawford SE, Stellmach V, Ranalli M, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001;114:4421-8.
173. Guan M, Pang CP, Yam HF, Cheung KF, Liu WW, Lu Y. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004.
174. Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003;9:774-80.
175. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003;8:72-9.
176. Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg 2003;126:28-38.
177. Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002;6:490-4.
178. Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001;189:323-33.
179. Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 2003;303:962-7.
180. Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 2004;316:573-9.
181. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
182. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A 2000;97:12227-32.
183. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9.
184. Hagedorn M, Zilberberg L, Wilting J, et al. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res 2002;62:6884-90.
185. Chadderton NS, Stringer SE. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int J Biochem Cell Biol 2003;35:1052-5.
186. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991;129:896-900.
187. Pan H, Nguyen NQ, Yoshida H, et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 2004;45:2413-9.
188. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219-38.
189. Struman I, Bentzien F, Lee H, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A 1999;96:1246-51.
190. D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A 1995;92:6374-8.
191. D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 1999;13:692-704.
192. Baker EA, Stephenson TJ, Reed MW, Brown NJ. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 2002;55:300-4.
193. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
194. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52.
195. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-80.
196. Moses MA, Wiederschain D, Wu I, et al. Troponin I is present inhuman cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 1999;96:2645-50.
197. Feldman L, Rouleau C. Troponin I inhibits capillary endothelial cell proliferation by interaction with the cell's bFGF receptor. Microvasc Res 2002;63:41-9.
198. Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999;94:2461-8.
199. Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-56.
200. Yao L, Pike SE, Pittaluga S, et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 2002;51:358-66.
201. Yao L, Pike SE, Tosato G. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 2002;71:47-53.
202. Xiao F, Wei Y, Yang L, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 2002;9:1207-13.
203. Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ Jr. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist 1999;4:501-8.
204. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-31.
205. Davis DW, Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004;10:33-42.
206. Bukowski RM. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 2003;12:1403-11.
207. Chamberlain J. Transforming growth factor-β: a promising target for anti-stenosis therapy. Cardiovasc Drug Rev 2001;19:329-44.
208. Westphal JR. Technology evaluation: ABT-510, Abbott. Curr Opin Mol Ther 2004;6:451-7.
209. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165-72.